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http://dx.doi.org/10.1053/j.gastro.2017.01.050BACKGROUND & AIMS: Persons with hepatitis C virus (HCV)
infection are at risk of progressive liver disease, cirrhosis, and
decompensation. We analyzed the effects of the direct-acting
antiviral agents elbasvir and grazoprevir in patients with HCV
infection and compensated cirrhosis, combining data from 6
clinical trials. METHODS: We performed an integrated analysis
of 402 patients with HCV genotype 1, 4, or 6 infection and
Child-Pugh A compensated cirrhosis enrolled in 6 clinical trials.
All patients received elbasvir/grazoprevir 50 mg/100 mg once
daily, with or without ribavirin, for 1218 weeks. The primary
end point was sustained virologic response 12 weeks after
completion of therapy (SVR12), defined as a level of HCV RNA
<15 IU/mL. RESULTS: Among treatment-naïve and treatment-
experienced patients receiving elbasvir/grazoprevir for 12
weeks, 97.8% (135 of 138) and 88.9% (48 of 54) achieved
SVR12, respectively. Among patients receiving elbasvir/
grazoprevir for 12 weeks, addition of ribavirin did not increase
the proportion of treatment-naïve patients (90.3%, 28 of 31) or
treatment-experienced patients who achieved an SVR12
(91.4%, 74 of 81). All (49 of 49) treatment-experienced pa-
tients receiving elbasvir/grazoprevir with ribavirin for 16 or 18
weeks, and 93.9% (46 of 49) of patients receiving elbasvir/
grazoprevir without ribavirin for 16 or 18 weeks achieved
SVR12. Virologic failure was higher among patients with HCV
genotype 1a infections compared with patients with genotype
1b or 4 infections, particularly in patients who had not
responded to previous interferon therapy. Baseline tests for
resistance-associated substitutions (RASs) led to an individu-
alized approach for selecting treatment duration and estab-
lished a need for ribavirin for patients with HCV genotype 1a
infection and RASs, regardless of treatment history. Among
patients with HCV genotype 1a infection with and without
baseline RASs in HCV nonstructural protein 5A who received
elbasvir/grazoprevir for 12 weeks, 73% (8 of 11) and 98% (96
of 98) achieved SVR12, respectively. Both patients with HCV
genotype 1a infection with baseline RASs who received 16 or
18 weeks of elbasvir/grazoprevir and ribavirin achieved
SVR12. Grade 3 or 4 increases in levels of alanine amino-
transferase and aspartate aminotransferase, which did not
cause symptoms, were reported in 2.3% (6 of 264) of patients
receiving elbasvir/grazoprevir. Serious adverse events were
reported in 3% (8 of 264) patients and no patient had a
decompensation-related event. CONCLUSIONS: In an analysis
of data from 6 clinical trials, rates of SVR12 ranged from 89%to 100% in patients with HCV genotype 1, 4, or 6 infections and
compensated cirrhosis treated with elbasvir/grazoprevir, with
or without ribavirin. Addition of ribavirin to a 12-week regimen
of elbasvir/grazoprevir had little effect on the proportion of
treatment-naïve or treatment-experienced patients who ach-
ieved an SVR12. However, virologic failure did not occur in any
treatment-experienced patients when the duration of elbasvir/
grazoprevir and ribavirin therapy was extended to 16 or 18
weeks. Baseline analysis of RASs (or in the absence of this test,
a history of nonresponse to interferon) can be used to
determine treatment duration and the need for ribavirin in
patients with HCV genotype 1a infection. Clinicaltrials.gov ID:
NCT02092350, NCT02105662, NCT02105467, NCT02105701,
NCT01717326, and NCT02105454.Keywords: NS5A; Virus Mutation; Fibrosis; ALT.
eople infected with the hepatitis C virus (HCV) are atPrisk of progressive liver disease, which ultimately
leads to cirrhosis and sequelae such as decompensation and
hepatocellular carcinoma. The estimated prevalence of
cirrhosis 20 years after initial infection is 16%.1 In patients
with cirrhosis (METAVIR F4 on biopsy), the estimated risk
of progression to hepatic decompensation events or hepa-
tocellular carcinoma is 37.2% at 5 years.2 Estimates suggest
that a period of 40 years will elapse between the peak
incidence of HCV infection (in the 1980s) and the
peak prevalence of HCV-related cirrhosis, implying that
HCV-related cirrhosis will peak during the 2020s at an
estimated 1.04 million cases.3
EDITOR’S NOTES
BACKGROUND AND CONTEXT
Treatment of HCV-infected cirrhotic patients with all-oral
regimens can require the addition of ribavirin and/or
extension of therapy beyond 12 weeks, particularly in
those with GT1a infection and/or interferon experience.
NEW FINDINGS
SVR12 was achieved by 98% and 89% of treatment-naïve
and -experienced compensated cirrhotic patients
receiving elbasvir/grazoprevir for 12 weeks. Most
virologic failure were GT1a-infected with baseline RASs.
All treatment-experienced patients receiving 16 weeks of
elbasvir/grazoprevir with ribavirin achieved SVR12.
LIMITATIONS
This was a retrospective integrated analysis of HCV-
infected patients with compensated cirrhosis
encompassing significant heterogeneity in baseline
demographic and clinical features.
IMPACT
Elbasvir/grazoprevir was highly effective and safe in
patients with HCV GT1/4 infection with compensated
cirrhosis. Most patients achieved SVR with elbasvir/
grazoprevir for 12 weeks. GT1a patients with RASs
require extension of therapy to 16 weeks and addition of
ribavirin.
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RRecent studies have shown that treating HCV reduces
all-cause mortality, even in patients with cirrhosis4,5; how-
ever, patients with HCV infection and cirrhosis have long
been regarded as difficult to treat, typified by low response
rates and poor tolerability to interferon-based regimens.6,7
Although treatments have improved, with all-oral regi-
mens now the accepted standard of care, many patients
with cirrhosis still require intensified treatment regimens.8,9
Currently approved all-oral direct-acting antiviral regimens
for treatment-naïve and treatment-experienced compen-
sated cirrhotic patients with HCV genotype (GT)1 infection
include 12-week regimens of sofosbuvir/ledipasvir,
sofosbuvir/velpatasvir, and elbasvir/grazoprevir (EBR/
GZR; in the United States for all GT1b patients and GT1a
patients without baseline NS5A resistance variants, with 16
weeks of EBR/GZRþribavirin [RBV] for GT1a-infected
patients with baseline resistance-associated substitutions
[RASs]). Cirrhotic patients who are not suitable for these
regimens, such as those who have failed a prior treatment
regimen that included a direct-acting antiviral agent, might
need alternative regimens that require treatment durations
of 24 weeks or addition of RBV to attain high rates of sus-
tained virologic response at 12 weeks (SVR12).8,9
The combination of EBR, an HCV NS5A inhibitor, and
GZR, an NS3/4A protease inhibitor, has been shown to be a
safe and highly effective treatment for chronic HCV infection
in phase 2/3 clinical trials.1015 EBR/GZR is administered
once daily, without regard to food intake, and in vitro has
been shown to retain activity against many clinically rele-
vant RASs.1618 Phase 3 studies of EBR/GZR in patients
with HCV GT1, 4, or 6 infection have evaluated a diversepopulation of patients, including treatment-naïve11 and
treatment-experienced13,19 patients, and those with human
immunodeficiency virus (HIV) co-infection10 or stage 4/5
chronic kidney disease.12 In these populations, EBR/GZR
has a generally favorable tolerability profile, with very few
serious adverse events (AEs) or discontinuations due to AEs
seen in phase 2/3 studies to date.20 Alanine aminotrans-
ferase (ALT)/aspartate aminotransferase (AST) elevations
reported with high-dose GZR (400800 mg/d) in a phase
2 study21 are uncommon in patients who receive lower
doses of GZR (100 mg/d), occurring in <1% of patients and
generally resolving with continued therapy or scheduled
end of therapy.20
Patients with compensated, Child-Pugh A cirrhosis were
allowed entry into the EBR/GZR phase 2/3 clinical trial
program, and we have therefore conducted an integrated
analysis of 402 patients with HCV GT1, 4, or 6 infection and
compensated cirrhosis who received EBR/GZR alone or with
RBV in these studies.Methods
This is an integrated analysis of data from 6 international
phase 2/3 clinical trials. All studies were carried out in accor-
dance with the Declaration of Helsinki, current guidelines on
Good Clinical Practices, and local ethical and legal
requirements. All patients provided voluntary written informed
consent before trial entry. The detailed methodology and
primary outcomes from these studies have been published
previously (Phase 3: C-SURFER12 [Protocol PN052]; C-EDGE
CO-INFECTION10 [Protocol PN061]; C-EDGE TREATMENT-
NAÏVE11 [Protocol PN060]; C-EDGE TREATMENT EXPERI-
ENCED [Protocol PN068]19; Phase 2: C-WORTHY14,15 [Protocol
PN035]; and C-SALVAGE13,22 [Protocol PN048]). All co-authors
had access to the study data and reviewed and approved the
final manuscript.
Patients
Patients enrolled in these studies were aged older than 18
years and had chronic HCV GT 1, 4, or 6 infection and HCV RNA
at baseline >10,000 IU/mL. They were either treatment-naïve
or had previously failed HCV therapy with peginterferon/RBV
(PR) with or without a first-generation protease inhibitor
(boceprevir, telaprevir, or simeprevir).13 Treatment-
experienced patients had prior response categorized as prior
relapse (undetectable HCV RNA at end of treatment followed by
detectable HCV RNA during follow-up) or prior on-treatment
failure (prior partial or null response, protocol-defined as >2
log decline in HCV RNA but quantifiable or <2 log decline at
treatment week 12, respectively [patients with prior virologic
breakthrough on PR were not enrolled]). These studies collec-
tively enrolled a diverse group of patients with HCV infection.
Patients enrolled in the C-SURFER study had stage 4 or 5
chronic kidney disease with estimated glomerular filtration rate
1529 mL/min per 1.73 m2 and <15 mL/min per 1.73 m2,
respectively.12 Patients enrolled in C-EDGE CO-INFECTION
had HIV co-infection and were either naïve to antiretroviral
therapy or were receiving stable antiretroviral therapy with
tenofovir or abacavir, and either emtricitabine or lamivudine
plus raltegravir, dolutegravir, or rilpivirine.10 Patients enrolled
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with PR plus boceprevir, telaprevir, or simeprevir.13,22 In all
studies, patients with decompensated liver disease (presence
or history of ascites, esophageal or gastric variceal bleeding,
hepatic encephalopathy, or other signs of advanced liver dis-
ease) or evidence of hepatocellular carcinoma were excluded.
To be eligible for inclusion in the present integrated
analysis, patients were required to have had Child-Pugh A
compensated cirrhosis based on at least 1 of the following
criteria: liver biopsy consistent with METAVIR F4 at any time
before entry into the study; FibroScan >12.5 kPa within 12
months of study entry; or AST-to-platelet ratio index (APRI)
>2.0 and FibroTest >0.75 within 12 months of study entry.
Laboratory exclusion criteria differed between the original
treatment studies due to the different patient populations
enrolled; however, all patients met the inclusion criteria for
their initial treatment study, were considered cirrhotic ac-
cording to biopsy, FibroScan or FibroTest þ APRI criteria, and
all had either 6 or 7 Child-Turcotte-Pugh points.
Treatment
All patients received EBR/GZR 50 mg/100 mg once daily
with or without RBV (8001400 mg/d based on body weight),
administered either as a co-formulated fixed-dose combination
tablet or as separate entities. Treatment-naïve patients were
treated for 12 weeks and treatment-experienced patients were
treated for 12 or 16/18 weeks.
Outcomes
The primary end point of all 6 studies was SVR12, defined
as HCV RNA <15 IU/mL. Plasma HCV RNA levels were
measured using the COBAS AmpliPrep/COBAS TaqMan HCV
test (version 2.0, Roche Molecular Diagnostics, Branchburg, NJ)
with a lower limit of quantitation of 15 IU/mL. In all studies,
relapse was defined as detectable HCV RNA after the end of
therapy, after undetectable HCV RNA at the end of therapy.
Virologic rebound was defined as HCV RNA >1 log increase
from nadir while on treatment, and virologic breakthrough was
defined as HCV RNA above the lower limit of quantitation after
previously being below the lower limit of quantitation. Safety
and tolerability were assessed through the monitoring of AEs,
vital signs, and laboratory assessments.
Population sequencing was performed at baseline and at the
time of virologic failure. The specific NS5A loci evaluated were
any polymorphism at amino acid positions 28, 30, 31, and 93
based on data from the EBR/GZR phase 2/3 clinical program,
which indicate that only polymorphisms at these 4 positions
impact the efficacy of EBR/GZR.23 HCV RNA was reverse-
transcribed and amplified using reverse transcription polymer-
ase chain reaction followed by population sequencing of the
NS5A gene on an ABI Sequencer from samples with RNA levels of
1000 IU/mL. The limit of minority variant detection in the
population was approximately 20% of the viral population.
Analyses
This is an exploratory retrospective analysis of data from
phase 2/3 clinical trials. Efficacy analyses are based on the full
analysis set population, which includes all randomized patients
who received 1 or more doses of drug. The resistance analysis
population included all patients with baseline sequencingavailable and a treatment outcome of either SVR12 or virologic
failure.
The safety analysis was based on the all patients as treated
population, which includes all patients who received more than
1 dose of study medication. The integrated safety population
included an additional 62 treatment-naïve patients with Child-
Pugh A cirrhosis who were treated for 18 weeks with EBR/GZR
with or without RBV in the C-WORTHY studies14,15 who were
not included in the efficacy analyses. These studies showed that
an 18-week treatment regimen with or without RBV provided
no incremental benefit in terms of improved efficacy for
treatment-naïve patients compared with 12 weeks of therapy.
We therefore elected not to include an efficacy analysis of
treatment-naïve patients treated for 18 weeks.
Results
Patient Characteristics
A total of 402 patients with Child-Pugh A compensated
cirrhosis were included in the present analysis (Table 1).
Most patients were white (n ¼ 324 [81%]) with HCV GT1a
(n ¼ 219 [54%]) or 1b/other 1 (n ¼ 157 [39%]) infection
(Table 2). Overall, 42% were treatment-naïve and 58%
were treatment-experienced (including 34 patients who had
failed treatment on prior PR plus a first-generation protease
inhibitor), and 10% of patients (n ¼ 40) had HIV
co-infection. Seven patients with stage 4/5 chronic kidney
disease from the C-SURFER study were also included.
Cirrhosis was diagnosed by biopsy in 29% of patients, by
FibroScan in 64% of patients, and by APRI þ FibroTest in
7%. Of the 258 patients diagnosed by FibroScan, 36% had
FibroScan values >25.0 kPa. Albumin was <3.5 g/dL in 6%
of patients and platelet count was <100,000 cells/mL in
25% of patients.
Four patients discontinued treatment early due to rea-
sons unrelated to study medication: 2 patients died during
treatment (1 treatment-naïve patient due to coronary artery
disease and 1 treatment-experienced patient due to a motor
vehicle accident), and 2 treatment-experienced patients
discontinued treatment (1 due to noncompliance and 1 due
to lymphoma). No patients were lost-to-follow-up.
Virologic Response
In this integrated population of treatment-naïve cirrhotic
patients with HCV GT1 or 4 infection, SVR12 was achieved
by 97.8% (135 of 138) of patients receiving EBR/GZR for 12
weeks and 90.3% (28 of 31) of those receiving EBR/
GZRþRBV for 12 weeks (no treatment-naïve patients with
HCV GT6 infection were included in this analysis) (Figure 1).
Of the 138 patients not given RBV, 3 failed to achieve
SVR12: 1 patient died after completing treatment (coronary
artery disease unrelated to study drug) and there were 2
virologic failures (breakthrough, n ¼ 1; relapse, n ¼ 1). The
lower response in the EBR/GZRþRBV arm was likely due to
the small sample size; evaluable patients came from one
treatment arm in the phase 2 C-WORTHY study. Three
patients in the RBV-containing treatment arm experienced
virologic failure (2 patients with relapse and 1 on-treatment
breakthrough).
Table 1.Original Treatment Studies
Treatment group/protocol number Study Regimen Patients included, n
Treatment-naïve patients
5172-035 C-WORTHY EBR/GZR for 12 wk 29
5172-052 C-SURFER EBR/GZR for 12 wk 4
5172-060 C-EDGE TN EBR/GZR for 12 wk 70
5172-061 C-EDGE HIV EBR/GZR for 12 wk 35
5172-035 C-WORTHY EBR/GZRþRBV for 12 wk 31
Total 169
Treatment-experienced patients
5172-035 C-WORTHY EBR/GZR for 12 wk 14
5172-052 C-SURFER EBR/GZR for 12 wk 3
5172-068 C-EDGE TE EBR/GZR for 12 wk 37
5172-035 C-WORTHY EBR/GZRþRBV for 12 wk 12
5172-048 C-SALVAGE EBR/GZRþRBV for 12 wk 34
5172-068 C-EDGE TE EBR/GZRþRBV for 12 wk 35
5172-035 C-WORTHY EBR/GZR for 16/18 wk 11
5172-068 C-EDGE TE EBR/GZR for 16/18 wk 38
5172-035 C-WORTHY EBR/GZRþRBV for 16/18 wk 12
5172-068 C-EDGE TE EBR/GZRþRBV for 16/18 wk 37
Total 233
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EBR/GZR with or without RBV for 12 weeks, or EBR/GZR
with or without RBV for 16/18 weeks, SVR rates were
91.4% (74 of 81), 88.9% (48 of 54), 100% (49 of 49), and
93.9% (46 of 49), respectively (Figure 1). In the 12-week
arms, 3 treatment-experienced patients discontinued treat-
ment for reasons unrelated to treatment (motor vehicle
accident, noncompliance, lymphoma; no RBV, n ¼ 2; RBV,
n ¼ 1). Of the 98 treatment-experienced patients included in
the 16-/18-week analysis population, 49 received RBV
(of which 37 were treated for 16 weeks and 12 for 18
weeks) and 49 did not (of which 38 were treated for 16
weeks and 11 for 18 weeks). All cirrhotic patients receiving
EBR/GZRþRBV for 16/18 weeks achieved SVR (49 of 49,
100%, including 37 of 37 treated for 16 weeks) compared
with 93.9% (46 of 49) of patients in the no RBV group
treated. Complete details of all 18 patients with virologic
failure included in this integrated analysis (GT1a infection,
n ¼11; GT1b, n ¼ 2; GT1-other, n ¼ 1; GT4/6, n ¼ 3) are
provided in Supplementary Table 1.Predictors of Response
Subgroup analysis showed high rates of SVR12 across
all patient subgroups, regardless of treatment history or
baseline demographic characteristics (Table 3). Of partic-
ular note, SVR12 was high regardless of severity of
cirrhosis, as indicated by the generally high response rates
in patients with albumin <3.5 g/dL, platelets <100  103
cells/mL, and FibroScan values >25.0 kPa, although SVR12
tended to be slightly lower among the treatment-
experienced patients in these subgroups who were
treated for 12 weeks. There were no patients in this
analysis with albumin <3.0 g/dL at baseline. Sixteen
treatment-naïve patients and 20 treatment-experienced
patients had platelets <75  103 cells/mL; SVR wasachieved by 15 of the treatment-naïve and 18 of the
treatment-experienced patients, respectively.
In patients with GT1b infection, SVR was 100% among
both treatment-naïve and -experienced patients receiving
EBR/GZR without RBV for 12 weeks (56 of 56 in treatment-
naïve patients and 13 of 13 in treatment-experienced
patients). In patients with GT4 infection, SVR12 was 100%
(6 of 6) in treatment-naïve patients receiving EBR/GZR
without RBV for 12 weeks but was lower in treatment-
experienced patients treated for 12 weeks (4 of 6 [67%])
or for 16 of 18 weeks without RBV (1 of 2 [50%]). All 4
treatment-experienced patients with GT4 infection who
received EBR/GZRþRBV for 16 of 18 weeks achieved
SVR12. Among treatment-naïve patients receiving EBR/GZR
for 12 weeks (no RBV), SVR rates were 100% (33 of 33) and
97.1% (102 of 105) in those with baseline viral load
800,000 IU/mL and >800,000 IU/mL, respectively.
Among treatment-experienced patients receiving EBR/GZR
(no RBV) for 12 weeks, SVR rates were 92.9% (13 of 14)
and 87.5% (35 of 40) in those with baseline viral load
800,000 IU/mL and >800,000 IU/mL, respectively. All 36
treatment-experienced patients receiving EBR/GZRþRBV
for 16 weeks with baseline viral load >800,000 IU/mL
achieved SVR (100%, 36 of 36).
HCV GT1a-infected patients were most likely to have
virologic failure. Among patients with GT1a infection
receiving EBR/GZR without RBV for 12 weeks, SVR12 was
96.1% (73 of 76; 95% confidence interval [CI], 88.9%
99.2%) and 88.6% (31 of 35; 95% CI, 73.2%96.8%) in
treatment-naïve and treatment-experienced cirrhotic
patients, respectively (Table 3). A total of 3 treatment-naïve
and 4 treatment-experienced patients with GT1a-infection
failed to attain SVR: 2 patients discontinued treatment
for reasons unrelated to study medication (1 treatment-
naïve patient died after completing treatment and
1 treatment-experienced patient was discontinued due to
Table 2.Patient Demographic Characteristics
Characteristic Treatment-naïve (n ¼ 169) Treatment-experienced (n ¼ 233)
Male, n (%) 113 (66.9) 151 (64.8)
Age, y, mean (range) 55.8 (3282) 56.6 (1976)
Race, n (%)
White 131 (77.5) 193 (82.8)
Black 16 (9.5) 21 (9.0)
Asian 17 (10.1) 19 (8.2)
Other 5 (3.0) 0 (0)
Hispanic or Latino, n (%) 11 (6.5) 21 (9.0)
BMI, 30 kg/m2, n (%) 34 (20.1) 68 (29.2)
HCV genotype, n (%)
1a 96 (56.8) 123 (52.8)
1b or other 1 67 (40.9) 90 (38.7)
4 6 (3.6) 17 (7.3)
6 0 3 (1.3)
Baseline viral load, n (%)
800,000 IU/mL 37 (21.9) 49 (21.0)
>800,000 IU/mL 132 (78.1) 184 (79.0)
HIV co-infection, n (%) 35 (20.7) 5 (2.1)
Chronic kidney disease stage 4/5, n (%) 4 (2.4) 3 (1.3)
Prior treatment response, n (%)
Prior null NA 120 (51.5)
Prior on-treatment failure excluding null NA 54 (23.1)
Prior relapse NA 59 (25.3)
Direct-acting antiviral agent NA 34 (14.6)
Platelet count, n (%)
<100  103/mL 40 (23.7) 61 (26.2)
<75  103/mL 16 (9.5) 20 (8.6)
ALT, IU/L, mean (SD) 102.4 (69.5) 98.9 (61.3)
Albumin level, n (%)
<3.5 g/dL 9 (5.3) 16 (6.9)
<3 g/dL 0 (0) 1 (0.4)
Cirrhosis determination method, n (%)
Biopsy 43 (25.4) 72 (30.9)
AST-to-platelet ratio indexþFibroTest 12 (7.1) 17 (7.3)
FibroScan 114 (67.5) 144 (61.8)
12.615.0 kPa 33 (28.9) 35 (24.3)
15.120.0 kPa 40 (35.1) 33 (22.9)
20.125.0 kPa 10 (8.8) 14 (9.7)
>25.0 kPa 31 (27.2) 62 (43.0)
IL28B genotype, n (%)
CC 63 (37.3) 32 (13.7)
CT/TT 106 (62.7) 200 (85.8)
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LIVERnoncompliance; both had no NS5A RASs at baseline) and the
remaining 5 patients relapsed. Among the 35 treatment-
experienced GT1a patients receiving EBR/GZR for 12
weeks, there were 3 virologic failures, all of whom had prior
null or partial response to PR. All 3 patients with virologic
failure had treatment-emergent NS5A RASs (Supplementary
Table 1: patients 151237, 680432, and 680801). A full
description of the treatment outcomes in patients with HCV
GT1a infection, including SVR according to baseline viral
load, is presented in Supplementary Table 2.
Further analysis of patients with GT1a infection
receiving EBR/GZR for 12 weeks, based on the presence of
baseline NS5A RASs, was conducted in the resistance anal-
ysis population, which included patients with available
baseline RAS analysis and an outcome of either SVR or
virologic failure (Table 4). The 2 GT1a-infected patientsreceiving EBR/GZR for 12 weeks who discontinued treat-
ment for reasons unrelated to study medication were
excluded from the resistance analysis population. Among
patients with GT1a infection receiving EBR/GZR for 12
weeks, NS5A RASs were detected in 10.7% (8 of 75) of
treatment-naïve and 8.8% (3 of 34) of treatment-
experienced patients (Table 4). In treatment-naïve GT1a
patients receiving EBR/GZR for 12 weeks, SVR12 was ach-
ieved by 66 of 67 (98.5%) patients with no NS5A RASs at
baseline and 7 of 8 (87.5%) patients with baseline NS5A
RASs. Among treatment-experienced GT1a-infected patients
receiving EBR/GZR for 12 weeks, SVR12 was achieved by 30
of 31 (96.8%) patients with no NS5A RASs at baseline and 1
of 3 (33.3%) patients with baseline NS5A RASs (34 of 35
treatment-experienced patients with GT1a infection were
evaluable for resistance analysis, while 1 patient had
Figure 1. SVR12 (full
analysis set). aIncludes all
patients who received at
least 1 dose of study
medication). DC, discon-
tinuation; LTFU, lost-to-
follow up.
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6.9% (2 of 29) of treatment-experienced patients receiving
EBR/GZRþRBV for 16/18 weeks. All 29 treatment-
experienced patients receiving EBR/GZRþRBV for 16
weeks, including both those with NS5A RASs at baseline,
achieved SVR12.Safety and Tolerability
Frequently observed AEs, such as fatigue, headache,
nausea, and insomnia, were more common in patients
receiving RBV compared with those not receiving RBV
(Table 5). Drug-related AEs were also higher among patients
receiving RBV (42% vs 73.1%). There was one drug-related
serious AE in a 56-year-old cirrhotic white female who re-
ported severe abdominal pain without associated symptoms
on day 30 of treatment with EBR/GZR. Physical examination
revealed Murphy’s sign with no gallstones. Medication was
continued and causality for the pain was assessed as possibly
related to study medication; the symptoms resolved and did
not recur while continuing study medication.
Six patients discontinued treatment due to an AE: 2 were
receiving EBR/GZR (lymphoma, ALT elevation, which met
protocol-defined stopping rule) and 4 were receiving EBR/
GZRþRBV (uterine bleeding, tachycardia, depression, portal
vein thrombosis/colitis). There were 3 deaths (lymphoma,
motor vehicle accident, coronary artery disease), all unre-
lated to study medication. No patient showed signs of liver
decompensation during treatment or follow-up, as evi-
denced by presence of ascites, esophageal or gastric variceal
bleeding, hepatic encephalopathy, or severe coagulopathy
(international normalized ratio >2.5).
Among patients receiving EBR/GZR without RBV, there
were 5 patients with grade 3 (5.110.0 upper limit ofnormal) and 1 patient with grade 4 (>10 upper limit of
normal) ALT/AST elevations (Table 6 and Supplementary
Table 1). None of the patients were symptomatic, and the
4 of the 5 patients with grade 3 ALT elevations had peak
values occurring at treatment week 6 or later, ranging from
204 to 369 IU/L. One patient had a peak ALT of 211 IU/L at
treatment week 1. All 6 patients with ALT/AST elevations
achieved SVR12. The patient with a grade 4 ALT and AST
elevation was a 52-year-old cirrhotic Asian female on a
12-week treatment course. This patient’s eosinophils
increased from 0.8% at baseline to 8.8% at treatment week
10, and her international normalized ratio increased from
baseline levels of 1.1 to 1.3 at treatment week 10. This was
concurrent with a grade 4 ALT/AST elevation (668/459
IU/L) which resulted in the discontinuation of study medi-
cation. Her ALT/AST returned to within normal limits
(20 IU/L) at follow-up week 4 and she achieved SVR12. This
was a protocol-mandated discontinuation based on a
protocol-specified stopping rule, and the patient remained
otherwise asymptomatic. No patient with elevated ALT/AST
had concurrent increased total bilirubin, and no patient had
drug-induced liver injury or met criteria for Hy’s Law.
Regarding other laboratory tests, a decrease in hemoglobin
levels was predominantly observed in patients receiving
RBV.Discussion
This integrated analysis presents data from >400 HCV-
infected patients with compensated cirrhosis treated with
EBR/GZR and diverse patient characteristics, including
treatment-naive, interferon-experienced, HIV co-infected,
and advanced kidney disease. Consistent with a more
advanced Child-Pugh A population, 36% of patients had a
Table 3.Sustained Virologic Response 12 Weeks After Completion of Therapy Subgroup Analyses (Full Analysis Seta)
Variable
Treatment-naïve Treatment-experienced
12 wk no RBV 12 wk þRBV 12 wk no RBV 12 wk þRBV
16/18 wk
no RBV
16/18 wk
þRBV
Overall 135/138 (97.8) 28/31 (90.3) 48/54 (88.9) 74/81 (91.4) 46/49 (93.9) 49/49 (100.0)
16 wk of treatment — — 35/38 (92.1) 37/37 (100.0)
18 wk of treatment — — 11/11 (100.0) 12/12 (100.0)
Race
White 98/101 (97.0) 28/30 (93.3) 30/35 (85.7) 69/76 (90.8) 39/41 (95.1) 41/41 (100.0)
Black 15/15 (100.0) 0/1 (0.0) 13/14 (92.9) 3/3 (100.0) 2/2 (100.0) 2/2 (100.0)
Asian 17/17 (100.0) — 5/5 (100.0) 2/2 (100.0) 5/6 (83.3) 6/6 (100.0)
Other 5/5 (100.0) — — — — —
HCV genotype
1a 73/76 (96.1) 18/20 (90.0) 31/35 (88.6) 29/33 (87.9) 24/25 (96.0) 30/30 (100.0)
1b or 1 other 56/56 (100.0) 10/11 (90.9) 13/13 (100.0) 41/43 (95.3) 20/20 (100.0) 14/14 (100.0)
4 6/6 (100.0) — 4/6 (66.7) 4/5 (80.0) 1/2 (50.0) 4/4 (100.0)
6 — — — — 1/2 (50.0) 1/1 (100.0)
Baseline viral load
800,000 IU/mL 33/33 (100.0) 4/4 (100.0) 13/14 (92.9) 17/18 (94.4) 4/4 (100.0) 13/13 (100.0)
>800,000 IU/mL 102/105 (97.1) 24/27 (88.9) 35/40 (87.5) 57/63 (90.5) 42/45 (93.3) 36/36 (100.0)
Baseline albumin levelsb
3.03.5 g/dL 9/9 (100.0) — 1/2 (50.0) 6/6 (100.0) 1/1 (100.0) 7/7 (100.0)
3.5 g/dL 126/129 (97.7) 28/31 (90.3) 47/52 (90.4) 68/75 (90.7) 45/48 (93.8) 42/42 (100.0)
Platelet count
<100  103/mL 35/36 (97.2) 2/4 (50.0) 11/15 (73.3) 20/22 (90.9) 12/13 (92.3) 11/11 (100.0)
100  103/mL 99/101 (98.0) 26/27 (96.3) 37/39 (94.9) 53/58 (91.4) 34/36 (94.4) 38/38 (100.0)
Unknown 1/1 (100.0) — — 1/1 (100.0) — —
Age
<65 y 117/120 (97.5) 21/24 (87.5) 42/47 (89.4) 62/69 (89.9) 37/39 (94.9) 41/41 (100.0)
65 y 18/18 (100.0) 7/7 (100.0) 6/7 (85.7) 12/12 (100.0) 9/10 (90.0) 8/8 (100.0)
IL28B
CC 51/52 (98.1) 10/11 (90.9) 9/9 (100.0) 7/7 (100.0) 9/9 (100.0) 7/7 (100.0)
Non-CC 84/86 (97.7) 18/20 (90.0) 39/45 (86.7) 66/73 (90.4) 37/40 (92.5) 42/42 (100.0)
Unknown — — — 1/1 (100.0) — —
Cirrhosis determination method
Biopsy 38/38 (100) 4/5 (80.0) 24/26 (92.3) 17/17 (100.0) 14/14 (100.0) 15/15 (100.0)
APRIþFibroTest 8/8 (100) 3/4 (75.0) 1/1 (100.0) 7/9 (77.8) 3/3 (100.0) 4/4 (100.0)
FibroScan 89/92 (96.7) 21/22 (95.5) 23/27 (85.2) 50/55 (90.9) 29/32 (90.6) 30/30 (100)
FibroScan value, kPa
12.615.0 25/25 (100) 7/8 (87.5) 6/7 (85.7) 12/12 (100.0) 10/10 (100.0) 6/6 (100.0)
15.120.0 30/31 (96.7) 9/9 (100.0) 3/3 (100.0) 14/14 (100.0) 7/8 (87.5) 8/8 (100.0)
20.125.0 6/6 (100) 4/4 (100.0) 3/3 (100.0) 6/8 (75.0) 2/2 (100.0) 1/1 (100.0)
>25.0 28/30 (93.3) 1/1 (100.0) 11/14 (78.6) 18/21 (85.7) 10/12 (83.3) 15/15 (100.0)
Prior treatment response
PR/P/IFN prior null – – 31/34 (91.2) 23/28 (82.1) 27/29 (93.1) 29/29 (100.0)
PR/P/IFN prior partial response – – 5/7 (71.4) 7/7 (100.0) 8/8 (100.0) 8/8 (100.0)
PR/P/IFN prior relapse – – 12/13 (92.3) 12/12 (100.0) 11/12 (91.7) 12/12 (100.0)
DAA prior nonresponder – – – 7/7 (100.0) – –
DAA prior breakthrough – – – 11/13 (84.6) – –
DAA prior relapse – – – 10/10 (100.0) – –
DAA experienced – – – 4/4 (100.0) – –
NOTE. Values are presented as n (%).
APRI, AST-to-platelet ratio index; DAA, direct-acting antiviral; IFN, interferon; P, peginterferon; PR, peginterferon/RBV.
aIncludes all patients who received at least 1 dose of study medication.
bThere were no patients with albumin levels <3.0  103 cells/mL.
1378 Jacobson et al Gastroenterology Vol. 152, No. 6
CLINICAL
LIVERFibroScan score >25 kPa, and 25% of patients had a platelet
count <100,000 cells/mL at baseline.
These data demonstrate that cirrhotic patients with HCV
GT1 or 4 infection can achieve high rates of SVR12 with
EBR/GZR-based treatment regimens. In treatment-naïve
patients, SVR12 was 98% among cirrhotic patients treatedfor 12 weeks, with no incremental benefit of concomitant
RBV therapy, and a 16-week/18-week treatment duration
with concomitant RBV in treatment-experienced patients,
resulted in a SVR12 of 100%.
High efficacy was maintained across all important
patient subgroups, including those with platelet counts
Table 4. Impact of NS5A Resistance-Associated Substitutions on Sustained Virologic Response 12 Weeks After Completion of
Therapy in Patients with Hepatitis C Virus GT1a Infection (Resistance Analysis Populationa)
SVR12
Treatment-naïve Treatment-experienced
EBR/GZR
for 12 wkb
EBR/GZRþRBV
for 12 wk
EBR/GZR
for 12 wkb
EBR/GZR þRBV
for 12 wk
EBR/GZR
for 16/18 wk
EBR/GZRþRBV
for 16/18 wkc
All patients, n (%) [95% CI] 73/75 (97.3)
[90.799.7]
18/20 (90.0)
[68.398.8]
31/34 (91.2)
[76.398.1]
29/32 (90.6)
[75.098.0]
24/25 (96.0)
[79.699.9]
29/29 (100)
[88.1100]
With NS5A RASs,c n (%) 7/8 (87.5) 2/4 (50.0) 1/3 (33.3) 1/3 (33.3) 2/3 (66.7) 2/2 (100)
No NS5A RASs,c n (%) 66/67 (98.5) 16/16 (100.0) 30/31 (96.8) 28/29 (96.6) 22/22 (100.0) 27/27 (100)
aResistance analysis population included patients with sequence data available and who either achieved SVR12 or met criteria
for virologic failure. Three patients from the full analysis set were excluded from the resistance analysis population (EBR/GZR
for 12 wk, n ¼ 2; EBR/GZRþRBV for 16 wk, n ¼ 1). Population sequencing: limit of variant detection >25% of circulating viral
quasi-species (only samples >1000 IU/mL sequenced). Only substitutions at amino acids 28, 30, 31, and 93 were included.
bTwo patients (1 treatment-naïve and 1 treatment-experienced) who discontinued treatment early due to administrative rea-
sons were excluded from this analysis (1 patient died after completing treatment, before follow-up week 4, and the other
patient was discontinued due to noncompliance; both had no NS5A RASs at baseline). Among patients with relapse, 1 of 2
treatment-naïve patients and 2 of 3 treatment-experienced patients had NS5A RASs present at baseline.
cExcludes 1 treatment-experienced patient with unavailable sequence data who also achieved SVR12.
Table 6.Laboratory Assessments
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R<100,000 cells/mL, serum albumin <3.5g/dL, and
FibroScan scores >25 kPa, suggesting no decline in efficacy
with advanced compensated cirrhosis. The difference in
SVR rates between GT1a-infected treatment-naïve and
-experienced patients receiving EBR/GZR (no RBV) for 12
weeks (96% vs 89%) may be attributable to the limited
number of patients included in this analysis, although an
increased impact of RASs in treatment-experienced patients
cannot be excluded. Sarrazin and colleagues24 recently re-
ported that among patients with GT1 infection receiving
ledipasvir/sofosbuvir for 12 weeks, SVR12 was 99% and
96% in treatment-naïve patients without and with high-
impact baseline NS5A RASs (RASs conferring >100-fold
loss of sensitivity to ledipasvir at a frequency of at least
15%), respectively (P ¼ .066); whereas in treatment-
experienced patients, SVR rates in those without and withTable 5.Safety and Adverse Events
Variable
EBR/GZR
(n ¼ 264)
EBR/GZRþRBV
(n ¼ 193)
1 AEs 193 (73.1) 164 (85.0)
Fatigue 40 (15.2) 59 (30.6)
Headache 44 (16.7) 40 (20.7)
Nausea 11 (4.2) 26 (13.5)
Insomnia 8 (3.0) 25 (13.0)
Drug-related AEs 111 (42.0) 141 (73.1)
Serious AEs 8 (3.0) 6 (3.1)
Serious drug-related AEs 1 (0.4) 0 (0.0)
Deaths 1 (0.4) 1 (0.5)
Discontinued due to an AE 2 (0.8) 4 (2.1)
NOTE. Values are presented as n (%). Safety population
includes 62 additional patients enrolled in C-WORTHY
(treatment-naïve cirrhotic patients treated for 18 wk). Dis-
continuations due to AE: without RBV, lymphoma, and ALT
elevation; with RBV, uterine bleeding, tachycardia, depres-
sion, and portal vein thrombosis/colitis; placebo, rash.high-impact NS5A RASs were 97% and 65%, respectively
(P < .05).
In the absence of baseline NS5A RASs, a 12-week
RBV-free regimen resulted in high rates of SVR12 regard-
less of treatment history. In total, 11 GT1a-infected patients
with baseline NS5A RASs received 12 weeks of EBR/GZR, of
which 8 (73%) achieved SVR12, whereas 96 of 98 (98%) of
GT1a-infected patients without RASs at baseline achieved
SVR12. Although patient numbers are small in this cirrhotic
population, increasing treatment duration to 16 of 18 weeks
and adding concomitant RBV appeared to overcome the
effect of NS5A RASs, a finding similar to that seen in the non
cirrhotic population.19 These data also suggest that if thereVariable
EBR/GZR
(n ¼ 264)
EBR/GZRþRBV
(n ¼ 193)
Hemoglobin
Grade 2: 9.09.9 g/dL 2 (0.8) 18 (9.3)
Grade 3: 7.08.9 g/dL 0 (0.0) 8 (4.1)
Grade 4: <7.0 g/dL 0 (0.0) 0 (0.0)
ALT,a IU/mL
Grade 3: 5.110.0 ULN 5 (1.9) 1 (0.5)
Grade 4: >10.0 ULN 1 (0.4) 0 (0.0)
AST, IU/mL
Grade 3: 5.110.0 ULN 2 (0.8) 0 (0.0)
Grade 4: >10.0 ULN 1 (0.4) 0 (0.0)
Elevation of total bilirubin,a mg/dL
Grade 3: 2.65.0 ULN 1 (0.4) 12 (6.2)
Grade 4: >5.0 ULN 0 (0.0) 1 (0.5)
Direct bilirubin,a mg/dL
Grade 3: 2.65.0 ULN 3 (1.1) 8 (4.1)
Grade 4: >5.0 ULN 0 (0.0) 1 (0.5)
NOTE. Values are presented as n (%).
ULN, upper limit of normal.
aNo patient met the criteria for Hy’s law.
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RAS data are not available, efficacy may be optimized by
extending treatment with EBV/GZR to 16 weeks and adding
RBV.
Data from this analysis are based on population
sequencing with a sensitivity threshold of 20% to 25%. Next-
generation sequencing data are not available for this cohort of
cirrhotic patients; however, data from the EBR/GZR clinical
program indicate that population sequencing with a sensi-
tivity threshold of 20%25% and next-generation
sequencing with a 10% threshold both identify a compara-
ble small set of EBR RASs among which the efficacy of EBR/
GZR is reduced. Increasing next-generation sequencing
sensitivity to a 1% threshold identifies a broader group of
EBR RASs, but those have a smaller impact on SVR compared
with those identified by population sequencing.
EBR/GZR was generally well tolerated. Six patients dis-
continued treatment due to an AE, one of which was
considered drug-related (abdominal pain). Four patients
had late ALT elevations after initially normalizing on treat-
ment and 1 patient discontinued treatment due to a grade 4
ALT elevation with increased eosinophils. There were no
decompensation events in this generally healthy cirrhotic
population, and no other evidence of declining liver function
while on treatment.
Therapeutic treatment options for patients with
cirrhosis frequently involve extended treatment durations
of 24 weeks and/or the use of RBV. In an integrated analysis
of 513 cirrhotic patients receiving sofosbuvir/ledi-
pasvir±RBV, an overall SVR12 rate of 96% was achieved,
although SVR12 rates were slightly lower in treatment-
experienced patients treated for 12 weeks (90% vs 98%
in patients treated for 24 weeks). SVR rates were also lower
in treatment-experienced patients with platelet count
<75,000 cells/mL (SVR of 82%) and those with NS5A RASs
at baseline (SVR of 85% in cirrhotic patients receiving
sofosbuvir/ledipasvir for 24 weeks).25 The recommended
treatment regimen for treatment-experienced patients with
compensated cirrhosis is sofosbuvir/ledipasvir for 24
weeks, but a 12-week regimen with addition of RBV is also a
therapeutic option for patients who are eligible for RBV
therapy.26 A French randomized, multicenter study has
shown similar rates of SVR12 in patients with compensated
cirrhosis receiving sofosbuvir/ledipasvirþRBV for 12 weeks
compared with those receiving sofosbuvir/ledipasvir alone
for 24 weeks (96% vs 97%).27 In a randomized study of
patients with Child-Pugh A cirrhosis receiving paritaprevir/
ritonavir, ombitasvir, dasabuvir, and RBV for 12 or 24
weeks, SVR 12 was achieved by 91.8% and 95.9% of pa-
tients in the 12- and 24-week treatment arms, respec-
tively.28 Cirrhotic patients with HCV GT1a infection require
ombitasvir, paritaprevir/ritonavir plus dasabuvir and RBV
for 24 weeks.29 More recently, the combination of sofos-
buvir/velpatasvir has received approval as a 12-week
regimen for compensated cirrhotic patients with GT1a
infection, regardless of treatment history without need for
treatment extension or addition of RBV (including for prior
direct-acting antiviral failures).30 Data from the present
analysis suggest that SVR12 rates of 98% are achievablewith a regimen of EBR/GZR for 12 weeks in the 89%93%
of cirrhotic patients with HCV GT1a infection who have no
baseline NS5A RASs. In the small proportion of GT1a-
infected patients with NS5A RASs at baseline (6.9%
10.6% of patients in this analysis), extending therapy to 16
weeks and the addition of concomitant RBV can overcome
the negative impact of NS5A RASs.
This integrated analysis is subject to several limitations.
The analysis was not prespecified nor powered for statis-
tical comparison between treatment arms. Most patients
had well-compensated cirrhosis, and thus these data cannot
be extrapolated to patients with more advanced cirrhosis or
decompensated disease. Indeed, the use of EBR/GZR is
contraindicated in patients with Child-Pugh B or C cirrhosis.
Furthermore, subgroup analyses frequently include small
numbers of patients, including limited numbers of patients
with HCV GT4 or 6 infection. EBR/GZR is not approved for
the treatment of patients with HCV GT6 infection, whereas
the EBR/GZR prescribing information indicates that patients
with GT4 infection should be treated with 12 weeks if
treatment-naïve or 16 weeks with the addition of RBV if
treatment-experienced.31 In addition, small numbers of
patients are included in several of the patient subgroups
with baseline NS5A RASs or previous treatment failure that
are used to discriminate extended durations of treatment.
However, the conclusions from this analysis of cirrhotic
patients are supported by similar observations from larger
analyses of noncirrhotic patients receiving EBR/GZR, which
also endorse the use of RAS testing to define treatment
duration in patients with GT1a infection.31 Finally, the lab-
oratory criteria used to define cirrhosis differed across the
original treatment studies, and the presence of cirrhosis in
this analysis population was not based on a single uniform
set of diagnostic criteria.
In conclusion, EBR/GZR was highly efficacious in
compensated cirrhotic patients. Most patients in our anal-
ysis had HCV GT1a or 1b infection. Patients with GT1b
infection achieved high rates of SVR12 with all regimens
evaluated, including EBR/GZR for 12 weeks, regardless of
the presence or absence of RASs; whereas the presence of
NS5A RASs can be used to define the optimum treat-
ment regimen in patients with GT1a infection. If RAS
testing is unavailable, an alternative approach is to use
history of prior treatment failure to define an optimal
regimen. Only 1 patient discontinued treatment due to a
protocol-mandated stopping rule and no patient experi-
enced a decompensation-related event. These data suggest
that EBR/GZR for 12 weeks is a safe and effective treatment
option for the majority of compensated cirrhotic patients
with HCV GT1 infection. An intensified regimen with RBV
for 16 weeks is required for GT1a-infected patients with
baseline NS5A RASs.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://dx.doi.org/10.1053/
j.gastro.2017.01.050.
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Supplementary Table 1.Cirrhotic Patients With Virologic Failure During Phase 2/3 studies With Elbasvir/Grazoprevir±Ribavirin
Patient ID Race TN or TE Genotype Regimen VF Study
Prior
response IL28B
Baseline
viral load,
IU/mL
Fibrosis stage or
FibroScan score
NS3 RASs NS5A RASs
At baseline At failure At baseline At failure
Genotype 1a
150439 White TN 1a EBR/GZR 12 wk Relapse C-WORTHY NA CT 9868198 15.1 kPa WT A156A/T WT L31M, Q30R
435643 White TN 1a EBR/GZR 12 wk BT C-EDGE TN NA CC 1238923 METAVIR F4 Q80K, S122G V36M, (Q80K,
S122G), D168A
L31L/M Q30R, (L31M)
151237 White TE 1a EBR/GZR 12 wk Relapse C-WORTHY Null CT 16181385 13.8 kPa WT A156T WT H58D, Q30R
680432 White TE 1a EBR/GZR 12 wk Relapse C-EDGE TE PR partial
responder
CT 4305256 METAVIR F4 WT A156T Q30H (Q30H), H58D
680801 White TE 1a EBR/GZR 12 wk Relapse C-EDGE TE PR null
responder
TT 1297238 25.7 kPa Q80K (Q80K), A156T,
D168A
L31M Q30R, (L31M)
150402 White TN 1a EBR/GZRþRBV
12 wk
Relapse C-WORTHY NA TC 7310263 0.88 FibroTest Q80K, S122G (Q80K), (S122G),
D168Y
Q30L/Q,
Y93H/Y
(Q30L), (Y93H),
L31M
150442 White TN 1a EBR/GZRþRBV
12 wk
Relapse C-WORTHY NA CC 5808604 Stage 4 cirrhosis
(Ludwig Score)
I132V, Q80K (I132V),
(Q80K),
A156G
L31V,
Y93N
(L31V), (Y93N)
480048 White TE 1a EBR/GZRþ
RBV 12 wk
Relapse C-SALVAGE DAA failure CT 1756431 21.3 kPa V36L R155K V36L, R155K, A156T,
V158V/A, D168N
WT Q30R
680811 White TE 1a EBR/GZRþRBV
12 wk
Relapse C-EDGE TE PR null
responder
TT 2913905 22.0 kPa Q80K Y56H (Q80K), R155I,
D168V
Y93N (Y93N)
680817 White TE 1a EBR/GZRþRBV
12 wk
Relapse C-EDGE TE PR null
responder
CT 5066351 0.88 FibroTest WT WT L31M Q30R, (L31M)
680819 White TE 1a EBR/GZR 16/18
wk
Relapse C-EDGE TE PR null
responder
TT 2695122 30.8 kPa I170V R155K L31M Q30R, (L31M)
Genotype 1b
480043 White TE 1b EBR/GZRþRBV
12 wk
Relapse C-SALVAGE DAA failure TT 1793936 0.88 FibroTest T54S T54S
Y56F, Q80L, A156T/A,
V170I
L31M L31M
Y93H
680835 White TE 1b EBR/GZRþRBV
12 wk
Relapse C-EDGE TE PR null
responder
CT 673361 41 kPa WT WT L31M (L31M), Y93H
Genotype 1-other
150427 Black/AA TN 1-Other EBR/GZRþRBV
12 wk
BT C-WORTHY NA CT 12539741 14.6 kPa PCR
failure
PCR failure PCR
failure
PCR failure
Genotype 4/6
680853 White TE 4d EBR/GZR 12 wk Relapse C-EDGE TE PR null
responder
CT 2646439 28.0 kPa WT WT WT L28S, M31I
680841 White TE 4d EBR/GZRþRBV
12 wk
Relapse C-EDGE TE PR null
responder
CT 5122681 35.3 kPa WT WT P58T M31V, (P58T), Y93H
680836 White TE 4a EBR/GZR 16/18 wk Rebound C-EDGE TE PR null
responder
TT 1948530 32.5 kPa WT A156M/T/V,
D168A/G,
V170I
L28M, P58Y (L28M), P58D
680007 Asian TE 6a EBR/GZR 16/18 wk Rebound C-EDGE TE PR relapse CT 2020413 15.3 kPa a a a a
AA, African American; DAA, direct-acting antiviral; NA, not available; TE, treatment-experienced; TN, treatment-naïve; WT, wild-type.
aUnable to generate sequence data for this patient.
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Supplementary Table 2.Outcomes Among Patients With Hepatitis C Virus GT1a Infection
Variable
Treatment-naïve Treatment-experienced
12 wk no RBV
(n ¼ 76)
12 wk þRBV
(n ¼ 20)
12 wk no RBV
(n ¼ 35)
12 wkþRBV
(n ¼ 33)
16/18 wk no RBV
(n ¼ 25)
16/18 wkþRBV
(n ¼ 30)
SVR, n (%) 73 (96.1) 18 (90.0) 31 (88.6) 29 (87.9) 24 (96.0) 30 (100)
Virologic failure, n (%) 2 (2.6) 2 (10.0) 3 (8.6) 3 (9.1) 1 (4.0) 0 (0)
Nonvirologic failure, n (%) 1a (1.3) 0 (0) 1b (2.8) 1c (3.0) 0 (0) 0 (0)
SVR according to
baseline viral load, n/N (%)
800,000 IU/mL 13/13 (100) 3/3 (100) 6/6 (100) 6/6 (100) 3/3 (100) 6/6 (100)
>800,000 IU/mL 60/63 (95.2) 15/17 (88.2) 25/29 (86.2) 23/27(85.2) 21/22 (95.5) 24/24 (100)
aDeath due to coronary artery disease.
bDiscontinued due to noncompliance.
cDeath due to a motor vehicle accident.
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